Schrödinger, Inc. Provides Consolidated Software Revenue Guidance for the First Quarter and Total Revenue Guidance for the Full Year 2022
February 24, 2022 at 04:01 pm EST
Share
Schrödinger, Inc. provided consolidated software revenue guidance for the first quarter and total revenue guidance for the full year 2022. For the first quarter of 2022, software revenue is expected to range from $28 to $30 million.
For the year, the company's total revenue expected to range from $161 million to $181 million, representing 17% to 31% growth over 2021. Total software revenue expected to range from $126 million to $136 million, representing 11% to 20% growth over 2021.
Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.
SCHRÖDINGER, INC. 
